| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1375331 | Bioorganic & Medicinal Chemistry Letters | 2010 | 4 Pages |
Abstract
A series of 3-amino-6-aryl-pyridazines have been identified as CB2 agonists with high efficacy and selectivity against the CB1 receptor. Details of the investigation of structure–activity relationships (SAR) are disclosed, which led to the identification of pyridazine analogue 35, a compound with high potency in an in vivo model of inflammatory pain.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Robert J. Gleave, Paul J. Beswick, Andrew J. Brown, Gerard M.P. Giblin, Paul Goldsmith, Carl P. Haslam, William L. Mitchell, Neville H. Nicholson, Lee W. Page, Sadhana Patel, Susan Roomans, Brian P. Slingsby, Martin E. Swarbrick,